| Literature DB >> 30103695 |
Nina Steinemann1, Jens Kuhle2, Pasquale Calabrese3, Jürg Kesselring4, Giulio Disanto5, Doron Merkler6, Caroline Pot7, Vladeta Ajdacic-Gross1, Stephanie Rodgers1, Milo Alan Puhan1, Viktor von Wyl8.
Abstract
BACKGROUND: Multiple sclerosis (MS) is one of the most frequently observed neurological conditions in Switzerland, but data sources for country-wide epidemiological trend monitoring are lacking. Moreover, while clinical and laboratory MS research are generally well established, there is a gap in patient-centered MS research to inform care management, or treatment decisions and policy making not only in Switzerland but worldwide.Entities:
Keywords: Epidemiology; Health-related quality of life; Multiple sclerosis; Patient-reported outcomes; Switzerland
Mesh:
Year: 2018 PMID: 30103695 PMCID: PMC6088400 DOI: 10.1186/s12883-018-1118-0
Source DB: PubMed Journal: BMC Neurol ISSN: 1471-2377 Impact factor: 2.474
Fig. 1Study design of the Swiss Multiple Sclerosis Registry (SMSR)
Overview of assessments in the Swiss Multiple Sclerosis Registry
| Topics | Layer 2 (one-off Survey) | Layer 3 Baseline (one-off Survey) | Layer 3 Follow-up 1 (every 6 months) | Layer 3 Follow-up 2 (every 12 months) | Layer 4 (Medical chart review every 12 months) |
|---|---|---|---|---|---|
| Sociodemographic variables | |||||
| Personal information | X | X | X | ||
| Family and living situation | X | X | X | ||
| Education, profession | X | X | |||
| Working situation | X | X | |||
| Occupational changes due to MS | X | X | |||
| Societal context (e.g. disability insurance) | X | X | |||
| Disease course | |||||
| First symptoms | X | X | |||
| Symptoms ever, current | X | X | X | X | X |
| Symptoms changes (prior and after diagnosis) | X | ||||
| Disease stage, type of MS | X | X | X | X | X |
| EDSS-score | X | X | X | X | |
| Mobility | X | X | |||
| Relapses | X | X | X | X | |
| Age of disease progression | X | ||||
| Diagnostic process | |||||
| Age at first symptoms | X | ||||
| Time of first medical doctor visit | X | ||||
| Personal experience of diagnostic process | X | ||||
| Treatment | |||||
| Disease modifying treatment ever/current | X | X | X | X | X |
| Non-drug therapies | X | X | X | X | X |
| Side effects / adverse events | X | X | X | X | X |
| Therapy stop / interruption | X | X | X | X | |
| Interventions against side effects | X | X | X | X | |
| Alternative medicine | X | X | X | X | |
| Additional medicine / supplements | X | X | X | X | |
| Cannabis treatment | X | X | X | ||
| Comorbidities | |||||
| Comorbidities | X | X | X | X | |
| Medication for comorbidities | X | X | X | X | |
| Risk factors and family history | |||||
| Weight | X | X | |||
| Smoking behavior (and exposure) | X | X | |||
| Alcohol consumption | X | X | |||
| Nutrition | X | X | |||
| Previous medical history | X | ||||
| Childhood illnesses | X | ||||
| Vaccination | X | X | |||
| MS family history | X | X | |||
| Sun exposure | X | ||||
| Hormonal factors (only women) | X | ||||
| Nutrition and Lifestyle | |||||
| Nutrition change since diagnosis | X | X | |||
| Lifestyle change since diagnosis | X | X | |||
| Physical Activity | X | X | X | ||
| Care and medical aids | |||||
| Institutions visits | X | X | X | ||
| Care types | X | X | |||
| Contact with healthcare professionals | X | X | X | ||
| Specialists consultation | X | X | X | ||
| Confidence in specialists | X | X | |||
| Medical aids | X | X | |||
| Domestic assistance | X | X | |||
| Housework | X | X | |||
| Disclosure of MS | X | X | |||
| Quality of Life | |||||
| Health related quality of life (EQ-5D-5 L;WHO 5-item well-being index) | X | X | X | X | |
| Mental health | |||||
| Psychological well-being | X | X | X | X | |
| Depression | X | X | X | ||
| Burden of disease | |||||
| Individual burden (e.g. symptoms,...) | X | X | X | X | |
| Societal burden | X | X | X | ||
| Economic burden | X | ||||
Fig. 2Holistic ascertainment of determinants of health outcomes in individuals affected by MS